Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

radioligand therapyPositive

AI Analysis

Summary

Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, expected to be operational in 2028 as part of its $23 billion US manufacturing investment. The facility will be the fifth RLT site in the US and support cancer treatment capacity across the southern region.

Outcome Details

Groundbreaking for new radioligand therapy manufacturing facility in Denton, Texas

Importance:5/10

Sentiment:

0.70

manufacturingexpansionradioligand therapycancer treatmentUS supply chaincapital investmentfacility construction

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on May 7, 2026 1:00 PM

Read Original